Thu, Jul 31, 2014, 7:01 PM EDT - U.S. Markets closed

Recent

% | $
Click the to save as a favorite.

Ironwood Pharmaceuticals, Inc. Message Board

  • guyrogers3456 guyrogers3456 Jul 30, 2012 2:06 PM Flag

    Cantor Fitzgerald Reiterates Sell Rating, Lowers PT IRWD

    UPDATE: Cantor Fitzgerald Reiterates Sell Rating, Lowers PT on Ironwood Pharmaceuticals
    10:47a ET July 18, 2012 (Benzinga) In a report published Wednesday, Cantor Fitzgerald reiterated its Sell rating on Ironwood Pharmaceuticals (NASDAQ: IRWD), but lowered its price target from $10.00 to $7.00.

    Cantor Fitzgerald noted, “Ironwood reported a loss of ($0.38) in 2Q:12 that exceeded consensus estimates of ($0.32) due to greater-than-expected R&D and G&A spending. We are lowering our price target to incorporate assumptions of even bigger spending levels and delayed profitability until Linaclotide can attain blockbuster status in 2019. Though IRWD could be volatile ahead of the Linaclotide PDUFA, we believe that the stock is overvalued and could see a sell-off after that event once the company's key catalyst plays out.”

    Ironwood Pharmaceuticals closed on Tuesday at $13.25.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
IRWD
14.80-0.42(-2.76%)Jul 31 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.